Strategies for successful clinical management of schizophrenia with ziprasidone

Expert Opinion on Pharmacotherapy

Volumn 11, Issue 13, 2010, Pages 2199-2220

  Fagiolini, Andrea ^a   Caas, Fernando ^b   Gallhofer, Bernd ^c   Larmo, Ilkka ^d   Levy, Pedro ^e   Montes, José Manuel ^f   Papageorgiou, Georgios ^g   Zink, Mathias ^h   Rossi, Alessandro ⁱ  

^a UNIVERSITY OF SIENA   (Italy)

^b Hospital Dr Rodríguez Lafora   (Spain)

^c JUSTUS LIEBIG UNIVERSITY   (Germany)

^d Aurora Psychiatric Hospital   (Finland)

^e HOSPITAL DE SANTA MARIA   (Portugal)

^f Hospital del Sureste   (Spain)

^g EVANGELISMOS HOSPITAL   (Greece)

^h CENTRAL INSTITUTE OF MENTAL HEALTH   (Germany)

ⁱ UNIVERSITY OF L'AQUILA   (Italy)

Author keywords

Activation; Benzodiazepines; Co medication; Dosing; Effect of food; Efficacy; Insomnia; Rapid uptitration; Schizophrenia; Tolerability; Ziprasidone

Indexed keywords

AMISULPRIDE; ANTACID AGENT; ANTIPARKINSON AGENT; ARIPIPRAZOLE; BENZATROPINE; BENZODIAZEPINE DERIVATIVE; CHLORPROMAZINE; CIMETIDINE; DEXTROMETHORPHAN; HALOPERIDOL; LITHIUM; LORAZEPAM; OLANZAPINE; ORAL CONTRACEPTIVE AGENT; OXAZEPAM; PROPRANOLOL; QUETIAPINE; TEMAZEPAM; ZIPRASIDONE;

AGITATION; BIPOLAR DISORDER; CLINICAL TRIAL; DIETARY INTAKE; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MEGADOSE; EUROPE; EXTRAPYRAMIDAL SYMPTOM; HUMAN; INSOMNIA; LOW DRUG DOSE; MEDICAL INFORMATION; MEDICAL PRACTICE; MEDLINE; NATURALISTIC INQUIRY; PSYCHIATRIST; QT PROLONGATION; REVIEW; RISK ASSESSMENT; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SIDE EFFECT; TREATMENT OUTCOME;

ANTIPSYCHOTIC AGENTS; COMORBIDITY; HUMANS; PIPERAZINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; SCHIZOPHRENIA; THIAZOLES; TREATMENT OUTCOME;

EID: 77955824832     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.2010.507630     Document Type: Review

References (74)

1. Stahl SM, Shayegan DK. The psychopharmacology of ziprasidone: receptor-binding properties and real-world psychiatric practice. J Clin Psychiatry 2003;64(Suppl 19):6-12
2. Nemeroff CB, Lieberman JA, Weiden PJ, et al. From clinical research to clinical practice: a 4-year review of ziprasidone. CNS Spectr 2005;10(Suppl 17):1-20
3. Schmidt AW, Lebel LA, Howard HR Jr, Zorn SH. Ziprasidone: a novel antipsychotic agent with a unique human receptor binding profile. Eur J Pharmacol 2001;425:197-201
4. Kroeze WK, Hufeisen SJ, Popadak BA, et al. H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology 2003;28:519-526
5. Geodon Capsules and Injections for Intramuscular Use. USPI. LAB-0273-16.0. Revised November 2009. Available from: http://media.pfizer. com/files/products/uspi-geodon.pdf [Last accessed July 2010]
6. Citrome L. Using oral ziprasidone effectively: the food effect and dose-response. Adv Ther 2009;26:739-748
7. Zeldox Capsule. Summary of Product Characteristics. Revised 4 September 2009
8. Keck PE Jr, Versiani M, Potkin S, et al. Ziprasidone in Mania Study Group. Ziprasidone in the treatment of acute bipolar mania: a three-week, placebo-controlled, double-blind, randomized trial. Am J Psychiatry 2003;160:741-748
9. Potkin SG, Keck P, Giller E, et al. Ziprasidone in bipolar mania: efficacy across patient subgroups. Presented at the 157th Annual Meeting of the American Psychiatric Association; 1-6 May 2004; New York, USA
10. DelBello M, Findling RL, Wang PP, et al. Safety and efficacy of ziprasidone in pediatric bipolar disorder [abstract NR4-070]. Presented at the American Psychiatric Association 161st Annual Meeting; 3-8 May 2008; Washington DC, USA.
11. Komossa K, Rummel-Kluge C, Hunger H, et al. Olanzapine versus other atypical antipsychotics for schizophrenia [review]. Cochrane Database Syst Rev 2010;3:CD006654
12. Komossa K, Rummel-Kluge C, Hunger H, et al. Ziprasidone versus other atypical antipsychotics for schizophrenia [review]. Cochrane Database Syst Rev 2009;4:CD006627
13. Leucht S, Corves C, Arbter D, et al. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 2009;373:31-41
14. Thompson SG, Pocock SJ. Can meta-analyses be trusted? Lancet 1991;338:1127-1130
15. Davey Smith G, Egger M. Meta-analysis. Unresolved issues and future developments. BMJ 1998;316:221-225
16. Davey Smith G, Egger M, Phillips AN. Meta-analysis. Beyond the grand mean? BMJ 1997;315:1610-1614
17. Simpson GM, Glick ID, Weiden PJ, et al. Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder. Am J Psychiatry 2004;161:1837-1847
18. Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychol Rep 1962;10:799-812
19. National Institute of Mental Health. Clinical Global Impression (CGI). In: Guy W, editor, ECDEU assessment manual in psychopharmacology. US Department of health, education, and welfare, Rockville, MD; 1970. p. 217-222
20. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987;13:261-276
21. Addington D, Addington J, Maticka-Tyndale E, Joyce J. Reliability and validity of a depression rating scale for schizophrenics. Schizophr Res 1992;6:201-208
22. Addington DE, Pantelis C, Dineen M, et al. Efficacy and tolerability of ziprasidone versus risperidone in patients with acute exacerbation of schizophrenia or schizoaffective disorder: an 8-week, double-blind, multicenter trial. J Clin Psychiatry 2004;65:1624-1633
23. Zimbroff D, Warrington L, Loebel A, et al. Comparison of ziprasidone and aripiprazole in acutely ill patients with schizophrenia or schizoaffective disorder: a randomized, double-blind, 4-week study. Int Clin Psychopharmacol 2007;22:363-370
24. Komossa K, Rummel-Kluge C, Schmid F, et al. Quetiapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev 2010;1:CD006625
25. Grootens KP, van Veelen NM, Peuskens J, et al. Olanzapine in recent-onset schizophrenia and schizoaffective disorder: results of an 8-week double-blind randomized controlled trial. Schizophr Bull 2009. [Epub ahead of print]
26. Heinrichs DW, Hanlon TE, Carpenter WT Jr. The Quality of Life Scale: an instrument for rating the schizophrenic deficit syndrome. Schizophr Bull 1984;10:388-398
27. Kahn RS, Fleischhacker WW, Boter H, et al.; EUFEST Study Group. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet 2008;371:1085-1097
28. Daniel DG, Potkin SG, Reeves KR, et al. Intramuscular (IM) ziprasidone 20 mg is effective in reducing acute agitation associated with psychosis: a double-blind, randomized trial. Psychopharmacology (Berl) 2001;155:128-134
29. Brook S, Lucey JV, Gunn KP. Intramuscular ziprasidone compared with intramuscular haloperidol in the treatment of acute psychosis. Ziprasidone I.M. Study Group. J Clin Psychiatry 2000;61:933-941
30. Zyprexa Summary of Product Characteristics. ZY49M. Updated 15 January 2010. Available from: http://pi.lilly.com/us/zyprexa-pi.pdf [Last accessed July 2010]
31. Lesem MD, Zajecka JM, Swift RH, et al. Intramuscular ziprasidone, 2 mg versus 10 mg, in the short-term management of agitated psychotic patients. J Clin Psychiatry 2001;62:12-18
32. Swift RH, Harrigan EP, Cappelleri JC, et al. Validation of the behavioural activity rating scale (BARS): a novel measure of activity in agitated patients. J Psychiatr Res 2002;36:87-95
33. Citrome L. Comparison of intramuscular ziprasidone, olanzapine, or aripiprazole for agitation: a quantitative review of efficacy and safety. J Clin Psychiatry 2007;68:1876-1885
34. Simpson GM, Weiden P, Pigott T, et al. Six-month, blinded, multicenter continuation study of ziprasidone versus olanzapine in schizophrenia. Am J Psychiatry 2005;162:1535-1538
35. Addington DE, Labelle A, Kulkarni J, et al. A comparison of ziprasidone and risperidone in the long-term treatment of schizophrenia: a 44-week, double-blind, continuation study. Can J Psychiatry 2009;54:46-54
36. Breier A, Berg PH, Thakore JH, et al. Olanzapine versus ziprasidone: results of a 28-week double-blind study in patients with schizophrenia. Am J Psychiatry 2005;162:1879-1887
37. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979;134:382-389
38. Loebel A, Warrington L, Siu C, et al. Remission in schizophrenia: a comparison of 2 dose regimens of ziprasidone versus haloperidol treatment in a 3-year double-blind extension study [poster]. Presented at the 44th Annual Meeting of the American College of Neuropsychopharmacology (ACNP); 11-15 December 2005; Waikoloa, Hawaii, USA.
39. Andreasen NC, Carpenter WT, Kane JM, et al. Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiatry 2005;162:441-449
40. Kane JM, Khanna S, Rajadhyaksha S, Giller E. Efficacy and tolerability of ziprasidone in patients with treatment-resistant schizophrenia. Int Clin Psychopharmacol 2006;21:21-28
41. Sacchetti E, Galluzzo A, Valsecchi P, et al.; on behalf of the INITIATE Study Group. Ziprasidone vs clozapine in schizophrenia patients refractory to multiple antipsychotic treatments: the MOZART study. Schizophr Res 2009;113:112-121
42. Dufton BD, Siddique CM. Measures in the day hospital. I. The Global Assessment of Functioning Scale. Int J Partial Hosp 1992;8:41-49
43. Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand 1970;212(Suppl):11-19
44. Guy W. ECDEU Assessment Manual for Psychopharmacology. US Department of Health Education and Welfare Publication (ADM) 76-338. National Institute for Mental Health, Rockville, MD; 1976
45. Kaye NS. Ziprasidone augmentation of clozapine in 11 patients. J Clin Psychiatry 2003;64:215-216
46. Ziegenbein M, Kropp S, Kuenzel HE. Combination of clozapine and ziprasidone in treatment-resistant schizophrenia: an open clinical study. Clin Neuropharmacol 2005;28:220-224 (Pubitemid 41579619)
47. Ziegenbein M, Calliess IT. Clozapine and ziprasidone: a useful combination in patients with treatment-resistant schizophrenia. J Neuropsychiatry Clin Neurosci 2006;18:246-247
48. Zink M, Kuwilsky A, Krumm B, Dressing H. Efficacy and tolerability of ziprasidone versus risperidone as augmentation in patients partially responsive to clozapine: a randomized controlled clinical trial. J Psychopharmacol 2009;23:305-314
49. Kuwilsky A, Krumm B, Englisch S, et al. Long-term efficacy and tolerability of clozapine combined with ziprasidone or risperidone. Pharmacopsychiatry 2010 [Epub ahead of print]
50. Diaz-Marsa M, Sanchez S, Rico-Villademoros F; ZIP-IIG-79 Study Group. Effectiveness and tolerability of oral ziprasidone in psychiatric inpatients with an acute exacerbation of schizophrenia or schizoaffective disorder: a multicenter, prospective, and naturalistic study. J Clin Psychiatry 2009;70:509-517
51. Arango C, Gomez-Beneyto M, Brenlla J, et al.; ZIS Study Group. A 6-month prospective, observational, naturalistic, uncontrolled study to evaluate the effectiveness and tolerability of oral ziprasidone in patients with schizophrenia. Eur Neuropsychopharmacol 2007;17:456-463
52. Mamo D, Kapur S, Shammi CM, et al. A PET study of dopamine D2 and serotonin 5-HT2 receptor occupancy in patients with schizophrenia treated with therapeutic doses of ziprasidone. Am J Psychiatry 2004;161:818-825
53. Citrome L, Reist C, Palmer L, et al. Dose trends for second-generation antipsychotic treatment of schizophrenia and bipolar disorder. Schizophr Res 2009;108:238-244
54. Citrome L, Reist C, Palmer L, et al. Impact of real-world ziprasidone dosing on treatment discontinuation rates in patients with schizophrenia or bipolar disorder. Schizophr Res 2009;115:115-120
55. Mullins CD, Shaya FT, Zito JM, et al. Effect of initial ziprasidone dose on treatment persistence in schizophrenia. Schizophr Res 2006;83:277-284
56. Joyce AT, Harrison DJ, Loebel AD, et al. Effect of initial ziprasidone dose on length of therapy in schizophrenia. Schizophr Res 2006;83:285-292
57. Citrome L, Yang R, Glue P, Karayal ON. Effect of ziprasidone dose on all-cause discontinuation rates in acute schizophrenia and schizoaffective disorder: a post-hoc analysis of 4 fixed-dose randomized clinical trials. Schizophr Res 2009;111:39-45
58. Miceli JJ, Tensfeldt TG, Shiovitz T, et al. Effects of oral ziprasidone and oral haloperidol on QTc interval in patients with schizophrenia or schizoaffective disorder. Pharmacotherapy 2010;30:127-135
59. Gandelman K, Alderman JA, Glue P, et al. The impact of calories and fat content of meals on oral ziprasidone absorption: a randomized, open-label, crossover trial. J Clin Psychiatry 2009;70:58-62
60. Daniel DG, Zimbroff DL, Potkin SG, et al. Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo controlled trial. Neuropsychopharmacology 1999;20:491-505
61. Alptekin K, Hafez J, Brook S, et al. Efficacy and tolerability of switching to ziprasidone from olanzapine, risperidone or haloperidol: an international, multicenter study. Int Clin Psychopharmacol 2009;24:229-238
62. Rossi A, Vita A, Tiradritti P, Romeo F. Assessment of clinical and metabolic status, and subjective well-being, in schizophrenic patients switched from typical and atypical antipsychotics to ziprasidone. Int Clin Psychopharmacol 2008;23:216-222
63. Harvey PD. Ziprasidone and cognition: the evolving story. J Clin Psychiatry 2003;64(Suppl 19):33-39
64. Weiden PJ, Iqbal N, Mendelowitz AJ, et al. Best clinical practice with ziprasidone: update after one year of experience. J Psychiatr Pract 2002;8:81-97
65. Cohrs S, Meier A, Neumann AC, et al. Improved sleep continuity and increased slow wave sleep and REM latency during ziprasidone treatment: a randomized, controlled, crossover trial of 12 healthy male subjects. J Clin Psychiatry 2005;66:989-996
66. Saha S, Chant D, McGrath J. A systematic review of mortality in schizophrenia. Arch Gen Psychiatry 2007;64:1123-1131
67. De Hert M, Dekker JM, Wood D, et al. Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC). Eur Psychiatry 2009;24:412-424
68. Parsons B, Allison DB, Loebel A, et al. Weight effects associated with antipsychotics: a comprehensive database analysis. Schizophr Res 2009;110:103-110
69. Lieberman JA, Stroup TS, McEvoy JP, et al.; Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353:1209-1223
70. Harrigan EP, Miceli JJ, Anziano R, et al. A randomized evaluation of the effects of six antipsychotic agents on QTc, in the absence and presence of metabolic inhibition. J Clin Psychopharmacol 2004;24:62-69
71. Brook S, Walden J, Benattia I, et al. Ziprasidone and haloperidol in the treatment of acute exacerbation of schizophrenia and schizoaffective disorder: comparison of intramuscular and oral formulations in a 6-week, randomized, blinded-assessment study. Psychopharmacology 2005;178:514-523
72. Keck P Jr, Buffenstein A, Ferguson J, et al. Ziprasidone 40 and 120 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 4-week placebo-controlled trial. Psychopharmacology (Berl) 1998;140:173-184
73. Potkin SG, Keck PE Jr, Segal S, et al. Ziprasidone in acute bipolar mania: a 21-day randomized, double-blind, placebo-controlled replication trial. J Clin Psychopharmacol 2005;25:301-310
74. Brook S. A pilot study of intramuscular ziprasidone in the short-term treatment of patients with acute exacerbation of schizophrenia. Hum Psychopharmacol 2000;15:521-524